Lee Troy Schalop
CIK: 0002072339
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lantern Pharma Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- May 12, 2026LTRN
Lantern Pharma Inc.
Purchase(P)Direct48.5K shares at avg. $2.06$100K - Jan 9, 2026LTRN
Lantern Pharma Inc.
Award(A)DirectStock Option (Right to Buy)
25K shares- - Jan 9, 2026LTRN
Lantern Pharma Inc.
Award(A)DirectStock Option (Right to Buy)
18.5K shares- - Aug 19, 2025LTRN
Lantern Pharma Inc.
Award(A)DirectStock Option (Right to Buy)
5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 12, 2026 | LTRN Lantern Pharma Inc. | Purchase(P) | 48,544 | $2.06 | $100,001 | Direct |
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | Award(A) Stock Option (Right to Buy) | 18,460 | - | - | Direct |
| Aug 19, 2025 | LTRN Lantern Pharma Inc. | Award(A) Stock Option (Right to Buy) | 5,000 | - | - | Direct |
1-4 of 4 transactions
About Schalop Lee Troy
Schalop Lee Troy (SEC CIK 0002072339) files insider reports with the SEC as Director of Lantern Pharma Inc. (LTRN).
Signal8 holds 4 ownership filings by Schalop Lee Troy (1 Form 3, 3 Form 4), filed between Jul 30, 2025 and May 14, 2026. Those filings report 4 transactions, from Aug 19, 2025 to May 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schalop Lee Troy's filings is in DALLAS, TX.
Recent filings by Schalop Lee Troy
Other insiders filing for Lantern Pharma Inc. (LTRN)
- KEYSER D JEFFREY, Director
- Maccecchini Maria-Luisa, Director
- Chandru Vijay, Director
- Silberstein David S., Director
- Margrave David R., Chief Financial Officer
- Bhatia Kishor G., Chief Scientific Officer